-
 First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia
-
iPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluation
-
T1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated consistent long-term insulin independence de-risking the combined technologies for both companies
Sartorius collaborates with RoosterBio to advance downstream purification processes for the manufacture of exosomes
Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency.
FREDERICK, Md., Jan. 5, 2023 – The life science group Sartorius extended a strategic collaboration partnership agreement with RoosterBio Inc. (RoosterBio) to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency. [Read more…]
Cultivated Meat Market: Lab-Grown Meat Grows by Leaps and Bounds
Cultivated meat refers to meat created using cell culture techniques within a laboratory or manufacturing facility. It is produced by growing master cells collected from cattle, chicken, pigs, fish, lamb, and other livestock. Cultivated meat is ethically produced, because livestock is not used within the manufacturing processes beyond collecting the initial cells required for cell culture. [Read more…]
I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”
PALO ALTO, Calif., Dec. 21, 2022 — I Peace, Inc. has been awarded a “Special Recognition in Cell Therapy” during BioSpectrum Asia Excellence Award 2022 ceremony held in Singapore on December 2.
I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette. I Peace supports research institutions and pharmaceutical companies around the globe by providing clinical-grade iPSCs conforming with regulatory standards both in the U.S. and Japan. [Read more…]
iPSirius Wins $2M Award from European Innovation Council to Develop a Novel Stem Cell Vaccine to Help Cancer Patients Worldwide
iPSirius is creating a new frontier in stem cell-based cancer therapeutics by developing a vaccine to fight aggressive tumors.
Paris, France, 19th December 2022 – iPSirius is a European immunotherapy company that is working to bring a new range of off-the-shelf vaccines to cancer patients worldwide to improve their prognosis and quality of life. iPSirius has developed a pipeline of engineered induced pluripotent stem cell (iPS) vaccines using its proprietary iPVAC technology. [Read more…]
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 201
- Next Page »